https://www.glei.llc/en/https://www.glei.llc/en/abouthttps://www.glei.llc/en/researchhttps://www.glei.llc/en/publicationshttps://www.glei.llc/en/insightshttps://www.glei.llc/en/timelinehttps://www.glei.llc/en/newsroomhttps://www.glei.llc/en/contacthttps://www.glei.llc/en/topics/matsutakehttps://www.glei.llc/en/research/aihttps://www.glei.llc/en/research/longevityhttps://www.glei.llc/en/research/equityhttps://www.glei.llc/en/research/bioactivehttps://www.glei.llc/en/research/economicshttps://www.glei.llc/zh/https://www.glei.llc/zh/abouthttps://www.glei.llc/zh/researchhttps://www.glei.llc/zh/publicationshttps://www.glei.llc/zh/insightshttps://www.glei.llc/zh/timelinehttps://www.glei.llc/zh/newsroomhttps://www.glei.llc/zh/contacthttps://www.glei.llc/zh/topics/matsutakehttps://www.glei.llc/zh/research/aihttps://www.glei.llc/zh/research/longevityhttps://www.glei.llc/zh/research/equityhttps://www.glei.llc/zh/research/bioactivehttps://www.glei.llc/zh/research/economicshttps://www.glei.llc/en/content/longevity-economy-whitepaperhttps://www.glei.llc/zh/content/longevity-economy-whitepaperhttps://www.glei.llc/en/content/taurine-biomarker-reassessment-2025https://www.glei.llc/zh/content/taurine-biomarker-reassessment-2025https://www.glei.llc/en/content/msc-regulatory-milestone-2024https://www.glei.llc/zh/content/msc-regulatory-milestone-2024https://www.glei.llc/en/content/young-plasma-fda-reminder-2024https://www.glei.llc/zh/content/young-plasma-fda-reminder-2024https://www.glei.llc/en/content/alphafold-three-2024https://www.glei.llc/zh/content/alphafold-three-2024https://www.glei.llc/en/content/ai-discovery-evidence-gaphttps://www.glei.llc/zh/content/ai-discovery-evidence-gaphttps://www.glei.llc/en/content/taurine-animal-aging-2023https://www.glei.llc/zh/content/taurine-animal-aging-2023https://www.glei.llc/en/content/normal-aging-mice-reprogramming-2022https://www.glei.llc/zh/content/normal-aging-mice-reprogramming-2022https://www.glei.llc/en/content/altos-launch-2022https://www.glei.llc/zh/content/altos-launch-2022https://www.glei.llc/en/content/capital-and-clinical-milestoneshttps://www.glei.llc/zh/content/capital-and-clinical-milestoneshttps://www.glei.llc/en/content/alphafold-database-2021https://www.glei.llc/zh/content/alphafold-database-2021https://www.glei.llc/en/content/healthy-ageing-baseline-2020https://www.glei.llc/zh/content/healthy-ageing-baseline-2020https://www.glei.llc/en/content/healthspan-access-agendahttps://www.glei.llc/zh/content/healthspan-access-agendahttps://www.glei.llc/en/content/senolytic-human-feasibility-2019https://www.glei.llc/zh/content/senolytic-human-feasibility-2019https://www.glei.llc/en/content/stem-cell-retinal-patch-2018https://www.glei.llc/zh/content/stem-cell-retinal-patch-2018https://www.glei.llc/en/content/matsutake-polysaccharide-2017https://www.glei.llc/zh/content/matsutake-polysaccharide-2017https://www.glei.llc/en/content/bioactive-materials-evidence-chainhttps://www.glei.llc/zh/content/bioactive-materials-evidence-chainhttps://www.glei.llc/en/content/partial-reprogramming-2016https://www.glei.llc/zh/content/partial-reprogramming-2016